Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a report issued on Thursday morning. The firm issued a sell rating on the medical research company’s stock.

Organovo Stock Performance

Shares of ONVO opened at $2.41 on Thursday. The firm has a market capitalization of $4.10 million, a PE ratio of -2.84 and a beta of 0.45. Organovo has a 52-week low of $2.14 and a 52-week high of $21.96. The stock has a 50 day simple moving average of $4.92 and a 200 day simple moving average of $5.10.

Organovo (NASDAQ:ONVO) last released its earnings results on Wednesday, February 19th. The medical research company reported ($2.28) earnings per share for the quarter, topping the consensus estimate of ($2.52) by $0.24. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.05 million. Equities research analysts predict that Organovo will post -0.77 EPS for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.